HIPO — what changed in the latest 10-Q
A section-by-section comparison of HIPO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-30 vs the prior 10-Q · 2026-04-30
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +40 | −33 | ~32 | 98 |
| Market risk (Item 3) | Text added/removed | +40 | −33 | ~32 | 97 |
| Controls & procedures | Text added/removed | +40 | −33 | ~32 | 97 |
| Legal proceedings | Text added/removed | +40 | −33 | ~32 | 97 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +40 | −33 | ~32 | 97 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
Text removed vs the prior filing · source: 10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
Text removed vs the prior filing · source: 10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
Text removed vs the prior filing · source: 10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
Text removed vs the prior filing · source: 10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
Other information
Text added vs the prior filing · source: 10-Q · 2026-07-30
•our development, deployment, and use of artificial intelligence and machine learning technologies, including the risk that competitors or other third parties may incorporate such technologies into their products more quickly or more successfully than we do;
Issuance of common stock from stock plans and contingently issuable shares348,981 — 1.1 — — 1.1 — 1.1
Issuance of common stock from stock plans and contingently issuable shares385,839 — 1.3 — — 1.3 — 1.3
Distributions to noncontrolling interests— — — — — — (3.9)(3.9)
Net increase (decrease) in cash, cash equivalents, and restricted cash21.5 (7.0)
Text removed vs the prior filing · source: 10-Q · 2026-04-30
Comprehensive income (loss) attributable to Hippo$4.7 $(45.6)
Net cash provided by (used in) financing activities$3.7 $(6.0)
Net increase (decrease) in cash, cash equivalents, and restricted cash54.7 (52.6)
Policy acquisition costs deferred, net for the three months ended March 31, 2026 and 2025 were $11.3 million and $27.5 million, respectively. The Company amortized deferred policy acquisition costs of $11.9 million and $17.4 million for the three months ended March 31, 2026 and 2025, respectively.
The Company issued a surplus note on June 2, 2025 in the amount of $50.0 million with a fixed interest rate of 9.5% for a term of 15 years. The surplus note is callable by the Company in 7 years. Interest on the outstanding principal is payable on September 1 and March 1 every year. Payment of princ…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice